Table 3.

DAS28 and components thereof compared against TNF inhibitors at each time point

		6 months		12 months		18 months
		Coefficient (95% CI)	P value	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value
IL6Ri	DAS28	− 1.84 (− 2.57, − 1.11)	< 0.001	− 1.69 (− 2.30, − 1.07)	< 0.001	− 0.88 (− 1.90, 0.31)	0.087
	SJC	− 0.88 (− 1.95, 0.19)	0.110	− 1.25 (− 1.93, − 0.57)	0.001	− 1.85 (− 3.48, − 0.22)	0.030
	TJC	− 2.11 (− 4.46, 0.22)	0.080	− 1.48 (− 2.90, − 0.07)	0.040	0.25 (− 0.39, 0.88)	0.440
	ESR	− 22.00 (− 27.35, − 17.60)	< 0.001	− 15.00 (− 22.01, − 7.92)	< 0.001	− 15.93 (− 32.04, 0.18)	0.053
	VAS	− 8.50 (26.70, 8.70)	0.330	− 13.70 (− 35.36, 7.96)	0.210	− 6.89 (− 20.72, 6.94)	0.330
CTLA-4i	DAS28	− 0.33 (− 0.60, 1.25)	0.480	− 0.24 (− 1.50, 0.97)	0.690	0.81 (0.09, 1.53)	0.030
	SJC	− 0.79 (− 1.97, − 0.40)	0.190	− 0.76 (− 1.83, 0.32	0.170	− 1.57 (− 3.00, − 0.18)	0.030
	TJC	5.98 (− 3.21, 15.16)	0.200	1.65 (− 2.56, 5.86)	0.440	2.59 (− 0.26, 5.37)	0.080
	ESR	− 13.09 (− 25.55, − 0.63)	0.040	11.63 (− 25.67, 48.94)	0.540	− 3.02 (− 39.82, 33.78)	0.870
	VAS	− 4.22 (− 15.28, 6.82)	0.450	− 12.85 (− 34.52, 8.83)	0.240	25.49 (− 4.03, 55.00)	0.090

IL6Ri IL6 receptor inhibitor, CTLA-4i CTLA-4 inhibitor, SJC swollen joint count, TJC tender joint count, ESR (mm/hr), VAS Patient Global Visual Analogue scale